Atebimetinib (IMM-1-104) is a novel orally dual-MEK inhibitor with anti-pancreatic cancer activity [1].
In Vivo, Atebimetinib (IMM-1-104) and sotorasib were well-tolerated as single agents and in combination with each other across all dose levels tested. Both drugs demonstrated dose-dependent antitumor activity with tumor regressions noted at higher dose levels. Atebimetinib in combination with sotorasib produced deep regressions that were sustained longer than either drug alone.
References:
[1]. Peter J. King, et al. Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model. Mol Cancer Ther (2021) 20 (12_Supplement): P240.
In Vivo, Atebimetinib (IMM-1-104) and sotorasib were well-tolerated as single agents and in combination with each other across all dose levels tested. Both drugs demonstrated dose-dependent antitumor activity with tumor regressions noted at higher dose levels. Atebimetinib in combination with sotorasib produced deep regressions that were sustained longer than either drug alone.
References:
[1]. Peter J. King, et al. Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model. Mol Cancer Ther (2021) 20 (12_Supplement): P240.